Immunoassay Biomarker Test Menu Expansion Market Report 2026

The immunoassay biomarker test menu expansion market size has grown rapidly in recent years. It will grow from $0.53 billion in 2025 to $0.6 billion in 2026 at a compound annual growth rate (CAGR) of 12.2%. The growth in the historic period can be attributed to increasing prevalence of chronic and infectious diseases, rising adoption of immunoassay based diagnostic technologies in clinical laboratories, expansion of hospital diagnostic infrastructure and lab networks, growing awareness of early disease detection and preventive healthcare, increasing government funding for diagnostic research and laboratory modernization.

The immunoassay biomarker test menu expansion market size is expected to see rapid growth in the next few years. It will grow to $0.95 billion by 2030 at a compound annual growth rate (CAGR) of 12.4%. The growth in the forecast period can be attributed to rising demand for precision medicine and personalized biomarker profiling, increasing integration of AI and automation in diagnostic laboratories, expansion of companion diagnostics in drug development pipelines, growing adoption of multiplex and high throughput testing platforms, increasing focus on early cancer and chronic disease detection programs. Major trends in the forecast period include expansion of multiplex immunoassay panels for multi biomarker disease detection, increasing development of high sensitivity chemiluminescent immunoassay platforms, rising adoption of personalized medicine driven biomarker testing solutions, growing integration of automated laboratory immunoassay analyzers for high throughput testing, increasing demand for oncology and infectious disease biomarker assay expansion.

The increasing prevalence of chronic and lifestyle diseases is expected to propel the growth of the immunoassay biomarker test menu expansion market going forward. Chronic and lifestyle diseases are long-term health conditions such as heart disease, diabetes, obesity, and hypertension that persist over extended periods and require continuous medical care. The rising prevalence of these diseases is driven by aging populations and lifestyle-related risk factors such as poor dietary habits and physical inactivity, which are significantly contributing to the growing burden of chronic health conditions. Immunoassay biomarker test menu expansion supports enhanced disease detection by enabling laboratories to identify a broader range of disease-associated biomarkers, thereby improving early diagnosis, monitoring, and clinical decision-making. For instance, in April 2025, according to the US Centers for Disease Control and Prevention, a US-based government public health agency, in 2023, 76.4% of US adults reported at least one chronic condition, representing more than 194 million adults with ongoing health conditions that require regular monitoring and management. Therefore, the increasing prevalence of chronic and lifestyle diseases is expected to propel and support the growth of the immunoassay biomarker test menu expansion market.

Leading companies operating in the immunoassay biomarker test menu expansion market are focusing on developing advanced automated immunoassay panels, such as fully integrated immunoassay systems that streamline sample handling and result reporting within a single automated workflow, to reduce operator variability and increase laboratory throughput. Automated immunoassay panels are systems in which immunoassay tests are performed with minimal manual intervention through robotics or automated analyzers that manage sample preparation, reagent mixing, incubation, detection, and result output, improving consistency and turnaround time in clinical settings. For example, in May 2024, bioMérieux, a France-based healthcare technology company, launched the VIDA TBI (GFAP, UCH-L1) test for its automated immunoassay platforms VIDAS 3 and VIDAS KUBE, featuring high sensitivity for traumatic brain injury biomarkers, compatibility with on-demand automated workflows 24/7, and rapid result turnaround, aiding efficient clinical triage and reducing unnecessary imaging. The launch strengthens bioMérieux’s immunoassay test menu by expanding its neurological biomarker portfolio and addressing growing demand for rapid diagnostic solutions in emergency care settings. Additionally, it supports improved clinical decision-making by enabling timely and accurate detection of brain injury, enhancing patient management, and optimizing healthcare resource utilization.

In July 2024, Roche, a Switzerland-based healthcare technology company, acquired LumiraDx’s point-of-care technology business for an agreed purchase price of approximately $295 million plus up to $55 million in additional payments. With this acquisition, Roche aims to broaden its diagnostics portfolio by integrating a multi-assay point-of-care platform that combines immunoassay, clinical chemistry, and related tests, expanding access to decentralized diagnostic solutions and accelerating global testing capabilities in primary care. LumiraDx is a UK-based healthcare technology company specializing in an advanced point-of-care diagnostic platform capable of running a wide range of immunoassay and clinical chemistry tests on a single instrument, with potential for further molecular testing expansion.

Major companies operating in the immunoassay biomarker test menu expansion market are Tecan Trading AG, Euroimmun Medizinische Labordiagnostika AG, OPKO Health Inc., Autobio Diagnostics Co. Ltd., Promega Corporation, BioLegend Inc., Sekisui Diagnostics LLC, Boditech Med Inc., Dynex Technologies Inc., QuantuMDx Group Ltd., NanoEntek, J. Mitra & Co. Pvt. Ltd., Baebies, ALPCO Diagnostics, Micropoint Bioscience, Coris BioConcept, MiCo BioMed Inc., Kamiya Biomedical Company, Abionic SA, ANP Technologies Inc., Axis‑Biosciences / Axela, Epitope Diagnostics Inc., MedMira Inc., Nanōmix Inc.

North America was the largest region in the immunoassay biomarker test menu expansion market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunoassay biomarker test menu expansion market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the immunoassay biomarker test menu expansion market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The immunoassay biomarker test menu expansion market consists of sales of enzyme-linked immunosorbent assay kits, chemiluminescent immunoassay kits, fluorescent immunoassay kits, multiplex immunoassay panels, rapid diagnostic test kits, biomarker-specific reagents, calibration standards, and quality control materials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.